Scott Alban, PhD, JD, leads the AstraZeneca global intellectual property team, which is accountable for developing and implementing IP strategies across the business, supporting business development teams in the evaluation of new opportunities (eg, asset licences, M&A, and scientific collaborations) and ensuring R&D and commercial assets are appropriately protected. Alban’s team also works closely with the company’s litigation group on all IP litigation matters. He has experience working in nearly all aspects of IP law including patent prosecution, litigation, opinions, interferences, oppositions, licensing and other complex R&D transactions.